[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"insect-sting-allergy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:insect-sting-allergy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100576828","immunotherapy-for-the-treatment-of-hymenoptera-venom-allergy-in-real-life-conditions-100576828",false,"NCT06790368","Immunotherapy for the Treatment of Hymenoptera Venom Allergy in Real-life Conditions.","Prospective Clinical Follow-up to Evaluate the Safety of Immunotherapy for the Treatment of Hymenoptera Venom Allergy in Real-life Conditions.","Venox-23","Inclusion Criteria:\n\n* The study population consisted of allergic participants indicated for treatment with hymenoptera venom immunotherapy (Apis mellifera or Vespula spp.) according to standard clinical practice.\n* Participants of both sexes aged 14 years or more.\n* Participants who have not received immunotherapy with hymenoptera venom in the previous 5 years.\n* Participants who have agreed to take part in the study and sign the informed consent form. In the case of minors, the patient's parent or guardian must also sign.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Having received immunotherapy with hymenoptera venom during the 5 years prior to the start of the study.\n* Participants who do not agree to participate and\u002For do not sign the informed consent form.\n* Participants who do not comply with medical indications or do not cooperate with immunotherapy treatment.","ALL","14 Years",{"count":20,"type":21},80,"ESTIMATED","OBSERVATIONAL","Observational clinical follow-up to evaluate the safety of immunotherapy for the treatment of hymenoptera venom allergy in real-life conditions. It includes the evaluation of controlled and spontaneous stings. This study will be conducted in Spain (multicentric), multicentric and data will be collected prospectively.",[25,26,27],"Allergy, Insect Venom","Allergy Insect Stinging","Insect Sting Allergy",[29,30,31,32,33],"Allergy","Immunotherapy","Apis mellifera","Vespula sp","controlled sting","RECRUITING","2025-04-30",{"date":37,"type":38},"2025-05-01","ACTUAL",{"date":40,"type":38},"2025-01-01",{"date":42,"type":21},"2026-06-01",{"name":44,"class":45},"Inmunotek S.L.","INDUSTRY",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100576201","prospective-observational-study-to-evaluate-the-safety-of-immunotherapy-as-a-treatment-for-hymenoptera-venom-allergy-100576201","NCT06782217","Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy","Inclusion Criteria:\n\n1. The study population consisted of allergic participants indicated for treatment with immunotherapy with hymenoptera venom (Apis mellifera or Vespula spp.) according to standard clinical practice.\n2. Age equal to or older than 14 years, without gender differences.\n3. Not having received immunotherapy with hymenoptera venom in the previous 5 years.\n4. That they agree to participate in the study and sign the informed consent form. In the case of minors, the parent or guardian of the participant must also sign the informed consent form.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women.\n2. Having received immunotherapy with hymenoptera venom during the 5 years prior to the start of the study.\n3. Participants who do not agree to participate and\u002For do not sign the informed consent form.\n4. Participants who do not comply with the medical indications or do not show cooperation with respect to the immunotherapy treatment.\n5. Participants with oncological diseases under active treatment or with autoimmune diseases under immunosuppressive treatment.\n6. Participants in whom the administration of immunotherapy is contraindicated.",{"count":54,"type":21},120,"Observational study to evaluate the safety of immunotherapy as a treatment for Hymenoptera venom allergy, analyzing the adverse reaction to immunotherapy as well as the allergic reaction to a spontaneous hymenoptera sting. This study will be conducted in Spain (multicentric) and data will be collected prospectively.",[25,26,27],[29,58,31,59,60],"Immunothepary","Vespula spp.","Insect venom",{"date":62,"type":38},"2025-05-04",{"date":64,"type":38},"2024-09-01",{"date":66,"type":21},"2027-02-01",{"name":44,"class":45},9]